BMY Bristol Myers Squibb

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model focused on oral immunomodulatory and oncology drugs, primarily treating multiple myeloma and CML
• • FDA-approved volume-unlimited generics launched for Revlimid (2026), pomalidomide generics entering U.S. (Mar 2026), dasatinib generics active since Sept 2024
• • Strategic shift marked by drastic revenue declines (up to 78% U.S. for Abraxane) due to generic erosion and Medicare Part D redesign
• • Total expenses reduced 31% to $38.9B in 2025 driven by 72% drop in acquired IPRD spend and 14% SG&A cuts post productivity initiatives
• • No excess inventory in U.S. distribution channels despite widespread generic competition, reflecting tightly managed supply and demand forecasting

Risk Factors

• • FDA approval of Breyanzi in Dec 2025 for relapsed/refractory MZL after ≥2 systemic therapies, impacting market access and revenue
• • Exposure to Japan's approval landscape with multiple key drug approvals by Ministry of Health Labour and Welfare in 2025, critical for Asia Pacific growth
• • Dependence on strategic collaboration with BioNTech for co-development of pumitamig, a PD-L1/VEGF-A bispecific in oncology
• • Competitive threat from BioNTech partnership leveraging innovative bispecific technology against IO market leaders Opdivo and Yervoy
• • $2.0B expected cost savings by 2027 through expanded 2025 strategic productivity initiatives impacting R&D, manufacturing, and commercial functions

Management Discussion & Analysis

• • Revenue and YoY change: Not disclosed in provided section
• • Profitability or margin change: Not disclosed in provided section
• • Best and worst performing segment: Not disclosed in provided section
• • Cash flow and capital allocation: Not disclosed in provided section
• • Forward-looking: Management highlights multiple regulatory approvals, pipeline expansion via acquisitions and collaborations including Orbital Therapeutics and BioNTech, new radiopharmaceutical facility opened

What are the latest BMY SEC filings in 2026?

Bristol Myers Squibb (BMY) has filed a 10-K annual report on February 11, 2026, a 10-Q quarterly report on April 30, 2026, an 8-K current report on July 30, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did BMY file its most recent 10-K annual report?

Bristol Myers Squibb (BMY) filed its most recent 10-K annual report on February 11, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view BMY 10-Q quarterly reports?

Bristol Myers Squibb (BMY)'s most recent 10-Q quarterly report was filed on April 30, 2026. SignalX displays every BMY 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has BMY filed recently?

Bristol Myers Squibb (BMY)'s most recent 8-K was filed on July 30, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find BMY insider trading activity (Form 4)?

SignalX aggregates every BMY Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does BMY file with the SEC?

Bristol Myers Squibb (BMY) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new BMY filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Bristol Myers Squibb (BMY).

What is BMY's SEC CIK number?

Bristol Myers Squibb (BMY)'s SEC CIK (Central Index Key) number is 14272. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 14272 to look up all BMY filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find BMY return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Bristol Myers Squibb (BMY) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.